Phase I/II (AM1030-CREAM)
Third, and final, SAD group completed.
6 (6/12) patients in the first MAD group (1:2) dosed.
• Company to focus pipeline development on severe inflammation and fibrosis
• Subgroup analysis of AMAP102 Phase 2a OA study indicates clinical response
• Dosing has commenced in AM1030-CREAM Phase 1/2a study for atopic dermatitis